Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title Hits
17 Mar 2010 Monoclonal antibody BT-061 shows efficacy in the indication psoriasis 11
17 Mar 2010 HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN NON-SMALL CELL LUNG CANCER 10
17 Mar 2010 CytoDyn Begins Full Humanization of Cytolin 9
16 Mar 2010 Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis 33
16 Mar 2010 4-Antibody Announces a Long-Term Collaboration With Boehringer Ingelheim for Therapeutic Antibodies 33
16 Mar 2010 Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation of Beta Cell Function 46
15 Mar 2010 Innate Immune, Inc. Enters into a License and Commercialization Agreement with Cephalon Australia Pty Ltd 32
14 Mar 2010 XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack 36
12 Mar 2010 Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer 79
12 Mar 2010 XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes Patients 65
11 Mar 2010 BioInvent and Human Genome Sciences Announce Collaboration to Co-develop and Commercialize Therapeutic Antibodies 70
11 Mar 2010 Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer 75
09 Mar 2010 Successful Development of Broad Spectrum Human Monoclonal Antibodies Against Major Influenza Viruses (H1N1 and H5N1) 104
08 Mar 2010 Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold 90
08 Mar 2010 Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients 50
04 Mar 2010 CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy 77
02 Mar 2010 FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients 140
01 Mar 2010 GTC Provides Update on TG20 Monoclonal Antibody Targeting CD20 101
01 Mar 2010 arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies 3
24 Feb 2010 Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 66
24 Feb 2010 Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer 102
22 Feb 2010 Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva(R) in Patients with Non-Small Cell Lung Cancer 76
22 Feb 2010 Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint 93
18 Feb 2010 VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema 176
18 Feb 2010 FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia 79
16 Feb 2010 Thallion Pharmaceuticals and LFB biotechnologies sign definitive agreement to develop and commercialize treatment for E. Coli (STEC) infection 103
16 Feb 2010 New High Purity Immunoglobulin Enters Phase III in Europe and the US 90
11 Feb 2010 ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE 162
10 Feb 2010 Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day 85
09 Feb 2010 Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases 103
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1703

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics